Biocon has acquired a manufacturing unit of Acacia Lifesciences in Vizag for an undisclosed amount.
The company has acquired business assets of the pharmaceutical manufacturing unit of Acacia Lifesciences with effect from October 1, 2015 on a going concern basis. This unit is presently manufacturing advanced intermediates of potent active pharma ingredients (APIs) useful to the company’s business as well as for supply to third party customers. The USFDA approved facility would help Biocon in vertically integrating its oncology related abbreviated new drug application (ANDA) filings in the future.
The facility, which is spread over 45,000 square feet, was commissioned in 2008 and currently APIs produced in the plant are sold both in domestic as well international markets.
Company Profile : Biocon Ltd
Leave a Reply